• Link to LinkedIn
  • Link to Mail
Phone: +44 (0)1273 234667 | Email: info@enterprisetherapeutics.com
Enterprise Therapeutics
  • Home
  • About Us
    • Leadership Team
    • Board
    • Advisory Board
  • Scientific Strategy
  • Pipeline
  • Publications, News & Events
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / 2 / 20263 / November

Enterprise Therapeutics granted EMA orphan medicinal product designation for novel cystic fibrosis therapy, ETD001

November 17, 2026/in News/by admin
  • Investigational inhaled ENaC blocker developed to treat people with cystic fibrosis not benefitting from CFTR modulators
  • Positive opinion recognises potential of ETD001 in treating rare and severe disease
  • Decision follows successful Phase 2 clinical trial

Brighton, UK, 17 November 2026: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted ETD001 designation as an orphan medicinal product for the treatment of cystic fibrosis. This follows the announcement earlier this year of a positive Phase 2 clinical trial outcome of ETD0011, an investigational inhaled epithelial sodium channel (ENaC) blocker, designed to increase lung function by improving mucus clearance and reducing airway obstruction.

The EMA COMP opinion concluded that ETD001 meets the orphan-designation criteria, recognising disease rarity and the potential for ETD001 to provide clinically relevant benefit, including for people who are not eligible for CFTR modulator therapy. The recommendation was supported by clinical data from the Phase 2 ET-ENAC-03 study, which were indicative of lung function improvement. Orphan medicine designation offers a range of benefits, including market exclusivity once the therapy is on the market.

Dr John Ford, CEO, Enterprise Therapeutics, commented: “Orphan drug designation represents an important regulatory milestone for the ETD001 programme and for Enterprise Therapeutics. The decision by the EMA reflects the continued need for additional treatment options for people with cystic fibrosis, particularly those who are not able to benefit from CFTR modulators. We look forward to continuing the development of ETD001 in CF as well as other mucus congestion related respiratory diseases.”

Annabella Amatulli, Head of Regulatory Affairs, Enterprise Therapeutics, added: “Our regulatory strategy supports our global development plan for ETD001, aligned with our goal to provide improved therapeutic options for people with cystic fibrosis. The EMA’s orphan drug designation further validates the strength of the programme’s scientific rationale and outcomes of the Phase 2 clinical trial.”

Cystic fibrosis is estimated to affect over 100,000 people worldwide, and leads to reduced life expectancy. Failed mucociliary clearance and mucus congestion in the lungs leads to cycles of infection and inflammation and an ongoing decline in lung function.

For more information about Enterprise Therapeutics, visit www.enterprisetherapeutics.com

https://enterprisetherapeutics.com/wp-content/uploads/2018/05/Enterprise-Therapeutics-Logo-2.png 0 0 admin https://enterprisetherapeutics.com/wp-content/uploads/2018/05/Enterprise-Therapeutics-Logo-2.png admin2026-11-17 12:35:272026-11-17 12:35:27Enterprise Therapeutics granted EMA orphan medicinal product designation for novel cystic fibrosis therapy, ETD001

Archives

  • November 2026
  • May 2026
  • December 2025
  • November 2024
  • September 2024
  • July 2024
  • June 2024
  • January 2024
  • February 2022
  • June 2021
  • October 2020
  • August 2020
  • February 2020
  • January 2020
  • November 2019
  • October 2019
  • April 2019
  • March 2019
  • February 2019
  • October 2018
  • September 2018
  • April 2018
  • March 2018
  • September 2017
  • June 2017
  • April 2017
  • February 2017
  • November 2016
  • October 2016
  • March 2016
  • May 2015
  • February 2015

ENTERPRISE THERAPEUTICS

Enterprise is a clinical stage biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases of high unmet medical need and commercial opportunity. The company is based in the UK with offices at the Sussex Innovation Centre and in London Blackfriars.

Latest News

  • Enterprise Therapeutics granted EMA orphan medicinal product designation for novel cystic fibrosis therapy, ETD001November 17, 2026 - 12:35 pm
  • Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001May 12, 2026 - 9:04 am
  • Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic FibrosisDecember 9, 2025 - 11:31 am
  • Enterprise Therapeutics publishes on medicinal chemistry of ETD001, a novel inhaled ENaC blocker for treatment of Cystic FibrosisNovember 19, 2024 - 9:33 am

Categories

  • News
  • Publications

Contact Us

Sussex Innovation Centre,
University of Sussex,
Science Park Square,
Falmer, Brighton, BN1 9SB

info@enterprisetherapeutics.com
+44 (0)1273 234667

Privacy & Cookie Policy

© Copyright - Enterprise Therapeutics - powered by Enfold WordPress Theme
Scroll to top Scroll to top Scroll to top
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. To choose which cookies you would like to accept please change your Cookie Settings
Cookie SettingsPrivacy and Cookie PolicyACCEPT ALL
Manage Cookies

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience. View our Privacy and Cookie Policy.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
local_storage_support_testpersistentThe cookie is used in context with the local-storage function in the browser. This function allows the website to load faster by pre-loading certain procedures.
PHPSESSIDSession
rc::apersistentThis cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.
rc::cSessionThis cookie is used to distinguish between humans and bots.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
__widgetsettingspersistentThis cookie is set by Twitter - The cookie allows the visitor to share content from the website on to their Twitter profile.
Statistics
Statistics or analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
collect google-analytics.comSessionUsed to sen d data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels.
_ga enterprisetherapeutics.com2 yearsRegisters a unique ID that is used to generate statistical data on how the visitor uses the website.
_gat enterprisetherapeutics.com1 dayUsed by Google Analytics to throttle request rate
_gid enterprisetherapeutics.com1 dayRegisters a unique ID that is used to generate statistical data on how the visitor uses the website.
Marketing
Marketing or advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
CookieDurationDescription
IDE doubleclick.net1 yearUsed by Google DoubleClick to register and report the website user's actions after viewing or clicking one of the advertiser's ads with the purpose of measuring the efficacy of an ad and to present targeted ads to the user.
test_cookie doubleclick.net1 dayUsed to check if the user's browser supports cookies.
VISITOR_INFO1_LIVE179 daysTries to estimate the users' bandwidth on pages with integrated You Tube videos.
YSCSessionRegisters a unique ID to keep statistics of what videos from You Tube the user has seen.
yt-remote-cast-installedSessionStores the user's video player preferences using embedded You Tube video
yt-remote-connected-devicespersistentStores the user's video player preferences using embedded You Tube video
yt-remote-device-idpersistentStores the user's video player preferences using embedded You Tube video
yt-remote-fast-check-periodSessionStores the user's video player preferences using embedded You Tube video
yt-remote-session-appSessionStores the user's video player preferences using embedded You Tube video
yt-remote-session-nameSessionStores the user's video player preferences using embedded You Tube video
yt.innertube::nextIdpersistentRegisters a unique ID to keep statistics of what videos from You Tube the user has seen.
yt.innertube::requestspersistentRegisters a unique ID to keep statistics of what videos from You Tube the user has seen.
SAVE & ACCEPT
Powered by CookieYes Logo